Year |
Citation |
Score |
2018 |
Paulson KG, Voillet V, McAfee MS, Hunter DS, Wagener FD, Perdicchio M, Valente WJ, Koelle SJ, Church CD, Vandeven N, Thomas H, Colunga AG, Iyer JG, Yee C, Kulikauskas R, et al. Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nature Communications. 9: 3868. PMID 30250229 DOI: 10.1038/S41467-018-06300-3 |
0.361 |
|
2017 |
Colunga A, Pulliam T, Nghiem P. Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 24: 2035-2043. PMID 29217527 DOI: 10.1158/1078-0432.CCR-17-0439 |
0.403 |
|
2016 |
Aurelian L, Bollino D, Colunga A. The oncolytic virus ΔPK has multi-modal anti-tumor activity. Pathogens and Disease. PMID 27242376 DOI: 10.1093/Femspd/Ftw050 |
0.65 |
|
2015 |
Bollino D, Colunga A, Li B, Aurelian L. ∆PK oncolytic activity includes modulation of tumor cell milieu. The Journal of General Virology. PMID 26602205 DOI: 10.1099/Jgv.0.000353 |
0.676 |
|
2014 |
Colunga A, Bollino D, Schech A, Aurelian L. Calpain-dependent clearance of the autophagy protein p62/SQSTM1 is a contributor to ΔpK oncolytic activity in melanoma Gene Therapy. 21: 371-378. PMID 24553345 DOI: 10.1038/Gt.2014.6 |
0.643 |
|
2011 |
Colunga A, Li B, Aurelian L. Abstract 600: The HSV-2 oncolytic virus ΔPK induces multiple death and inflammatory programs associated with inhibition of melanoma tumor growth Cancer Research. 71: 600-600. DOI: 10.1158/1538-7445.Am2011-600 |
0.7 |
|
2010 |
Colunga AG, Laing JM, Aurelian L. The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins. Gene Therapy. 17: 315-27. PMID 19798049 DOI: 10.1038/Gt.2009.126 |
0.52 |
|
2008 |
Poff JA, Allen CT, Traughber B, Colunga A, Xie J, Chen Z, Wood BJ, Van Waes C, Li KC, Frenkel V. Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib. Radiology. 248: 485-91. PMID 18574138 DOI: 10.1148/Radiol.2482071674 |
0.312 |
|
Show low-probability matches. |